EULAV Asset Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

EULAV Asset Management’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-185,000	Closed	-$21.9M	–	229
2022 Q1	$21.9M	Sell	185,000 -67,000	-27%	-$8.36M	0.65%	53
2021 Q4	$35.1M	Sell	252,000 -35,000	-12%	-$4.45M	0.88%	37
2021 Q3	$39.9M	Sell	287,000 -78,000	-21%	-$9.74M	1.05%	28
2021 Q2	$35.4M	Buy	365,000 +20,000	+6%	+$1.62M	0.94%	33
2021 Q1	$23.6M	Buy	345,000 +45,000	+15%	+$3.64M	0.63%	58
2020 Q4	$25.7M	Sell	300,000 -104,427	-26%	-$8.85M	0.67%	49
2020 Q3	$26.3M	Buy	404,427 +13,427	+3%	+$880K	0.78%	38
2020 Q2	$28.6M	Buy	391,000 +21,000	+6%	+$1.12M	0.94%	33
2020 Q1	$12.6M	Buy	370,000 +110,000	+42%	+$5.03M	0.5%	70
2019 Q4	$14.2M	Buy	260,000 +40,000	+18%	+$1.98M	0.49%	72
2019 Q3	$9.18M	Buy	220,000 +110,000	+100%	+$4.65M	0.34%	89
2019 Q2	$4.82M	Buy	+110,000	New	+$6.2M	0.18%	132

Other funds holding BHVN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EULAV Asset Management's BHVN Position: Q2 2022 in Review

EULAV Asset Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2022, closing a stake of 185,000 shares — an estimated $21.9M sold.

EULAV Asset Management first reported a position in BHVN in Q2 2019 and held it in 12 quarters. The position peaked at $39.9M in Q3 2021. 329 funds tracked by Wall St. Rank hold BHVN as of Q2 2022.

EULAV Asset Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2022 after selling out during the quarter.
EULAV Asset Management sold 185,000 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2022, an estimated $21.9M.
EULAV Asset Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2019 and held it in 12 quarters.
EULAV Asset Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $39.9M in Q3 2021.
329 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2022.

Based on EULAV Asset Management's 13F filing for Q2 2022, filed 22 Jul 2022.